Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Knight Therapeutics Inc (KHTRF)

Knight Therapeutics Inc (KHTRF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.41
Trade KHTRF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.9100 +8.95%
on 04/03/24
4.2900 -0.70%
on 04/18/24
+0.2990 (+7.55%)
since 04/02/24
3-Month
3.8600 +10.36%
on 03/21/24
4.2900 -0.70%
on 04/18/24
+0.2100 (+5.19%)
since 01/30/24
52-Week
3.2010 +33.08%
on 10/02/23
4.2900 -0.70%
on 04/18/24
+0.8000 (+23.12%)
since 04/27/23

Most Recent Stories

More News
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 8.37 (+23.27%)
CNCE : 8.37 (+0.12%)
KYKOF : 17.6300 (+4.76%)
SFOSF : 1.5500 (+1.17%)
KHTRF : 4.2600 (+1.67%)
ACIU : 2.43 (-0.41%)
BMEA : 12.32 (+3.27%)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Brookdale Senior Living (BKD), Regeneron (REGN) and Knight Therapeutics (OtherKHTRF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Brookdale Senior Living (BKD – Research Report), Regeneron (REGN – Research Report) and Knight Therapeutics (KHTRF...

BKD : 7.36 (+2.36%)
REGN : 940.31 (+0.29%)
KHTRF : 4.2600 (+1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 4.3267
2nd Resistance Point 4.2933
1st Resistance Point 4.2767
Last Price 4.2600
1st Support Level 4.2267
2nd Support Level 4.1933
3rd Support Level 4.1767

See More

52-Week High 4.2900
Last Price 4.2600
Fibonacci 61.8% 3.8740
Fibonacci 50% 3.7455
Fibonacci 38.2% 3.6170
52-Week Low 3.2010

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar